Celsion Corporation (NASDAQ:CLSN) Q2 2020 Earnings Conference Call - Final Transcript
Aug 14, 2020 • 11:00 am ET
Good morning. My name is Cassidy, and I will be your operator today. At this time, I would like to welcome you all to Celsion's 2020 Second Quarter Financial Results Conference Call. [Operator Instructions] Following the speaker's remarks there will be question-and-answer session. [Operator Instructions].
At this time, I would like to turn the call over to Kim Golodetz. Please go ahead.
Kim Sutton Golodetz
Thank you, and good morning, everyone. This is Kim Golodetz with LHA. Welcome to Celsion Corporation's conference call to discuss its second quarter 2020 financial results. As has been Celsion's practice and as noted by the operator, prepared remarks will be followed by our question-and-answer period. Today's conference call will be archived, and the telephone replay will be available beginning later today through August 28, 2020. The webcast will be available for the next 90 days on Celsion's website.
During this call, management will be making forward-looking statements regarding Celsion's expectations and projections about future events. Generally, forward-looking statements can be identified by terminologies such as expects, anticipates, believes or other similar expressions. These statements are based on current expectations and are subject to a number of risks and uncertainties, including those set forth in the company's periodic filings with the Securities and Exchange Commission. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. In particular, there is significant uncertainty about the duration and contemplated impact of the COVID-19 pandemic. This means results could change at any time, and the contemplated impact of COVID-19 on Celsion's operations, financial results and outlook is a best estimate based on the information for today's discussion. I also caution that the content of this conference call is accurate only as of the date of the live broadcast, August 14, 2020. Celsion undertakes no obligation to revise or update comments made during this call, except as required by law.
With that said, I'd like to turn the call over to Michael Tardugno, Celsion's Chairman, CEO and President. Michael?
Michael H. Tardugno
Well, thank you, Kim. Good morning, everyone. It's always my pleasure to speak with you, particularly now. Joining me today is Jeffrey Church, our Executive Vice President and Chief Financial Officer, who will provide a review of Celsion's recent financial results in a few minutes. Also on the call for the Q&A and dialing in remotely is Dr. Nicholas Borys, our Executive Vice President and Chief Medical Officer.
We reported a great deal of news during the second quarter and recent weeks for both of our lead programs with much of it focused on ThermoDox, our Phase III OPTIMA Study for the treatment of newly diagnosed hepatocellular carcinoma or are also known as primary liver cancer because we recently held a conference call to address the unexpected results suggesting futility from the DMC's second preplanned interim efficacy analysis. I'll touch on where we are with the OPTIMA study and our analysis and some brief comments later in this call.
But first, I'd like to focus on the spate of positive